
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-04-02-2014
- Volume 10
- Issue 4
PhRMA Launches National Campaign to Increase Diversity in Clinical Trials
The I'm In campaign is designed to increase participation by diverse patient populations for clinical trials.
The
The I’m In campaign will raise awareness about the importance of clinical research and increase participation by diverse patient populations to help researchers develop potential new medicines. Partnerships with patient advocacy organizations, provider groups, individual physicians, clinical trials sponsors, and researchers will help to drive campaign awareness and involvement.
According to FDA, African Americans represent 12% of the US population but only 5% of clinical trial participants and Hispanics make up 16% of the population but only 1% of clinical trial participants. Inclusion of individuals of varied races, ethnicities, ages, gender, and sexual orientation in clinical trials can help to prevent disparities in the evaluation of potential new medicines.
I’m In will support the National Minority Quality Forum’s Clinical Trial Engagement Network, a solution to help accelerate the inclusion of underrepresented populations in clinical trials. Authorized users will be able to identify potential clinical trial participants by using zip code level mapping of disease clusters and simultaneously identifying and connecting points of care and community resources that can assist with site selection and patient recruitment.
Source:
Articles in this issue
about 12 years ago
Pharma Industry Corruption in China Under Scrutinyabout 12 years ago
Western CMOs Rise Again, Face New Challengesabout 12 years ago
How Will CMO Ownership Changes Impact Market?about 12 years ago
Synthetic Biology Stirs Interest in Greener, More Efficient Processesabout 12 years ago
Covance Expands Global Biologics Capabilitiesabout 12 years ago
Vetter Implements New Serialization Servicesabout 12 years ago
AmerisourceBergen Acquires Minority Interest in Profarmaabout 12 years ago
Catalent Increases Investment in Redwood Bioscience



